BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12668287)

  • 1. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
    Nakayama K; Takebayashi Y; Nakayama S; Hata K; Fujiwaki R; Fukumoto M; Miyazaki K
    Cancer Lett; 2003 Mar; 192(2):227-35. PubMed ID: 12668287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
    Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
    Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
    van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
    J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
    Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
    Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
    Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of DNA quantification in early epithelial ovarian carcinoma.
    Valverde JJ; Martin M; García-Asenjo JA; Casado A; Vidart JA; Díaz-Rubio E
    Obstet Gynecol; 2001 Mar; 97(3):409-16. PubMed ID: 11239647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
    Shahin MS; Hughes JH; Sood AK; Buller RE
    Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
    Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
    Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.
    Miyashita H; Nitta Y; Mori S; Kanzaki A; Nakayama K; Terada K; Sugiyama T; Kawamura H; Sato A; Morikawa H; Motegi K; Takebayashi Y
    Oral Oncol; 2003 Feb; 39(2):157-62. PubMed ID: 12509969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
    Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
    Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary.
    Daponte A; Guidozi F; Tiltman AJ; Marineanu A; Taylor L
    Anticancer Res; 1999; 19(3B):2387-9. PubMed ID: 10472362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.